See how the switch to CABENUVA may benefit patients, like yours
"Unfortunately, sometimes having a bottle in your medicine cabinet, you know, it just gives you away."
It starts with recognizing there are some patients who could benefit from a long-acting regimen
Patients entering SOLAR on BIKTARVY revealed challenges with taking continuing daily oral therapy at baseline
On Day 1, patients in SOLAR (N=670; mlTT-E) responded to 3 baseline questions about their previous experience on a daily oral therapy (exploratory endpoint).1
47%
of patients in SOLAR reported experiencing at least one of the following challenges always or often*:
- Worried about people unintentionally discovering their HIV status
- Worried about forgetting to take their HIV medication
- Felt that taking their HIV medication was an uncomfortable reminder of their HIV status
These results are descriptive in nature and should not be used to infer clinical significance.
- Patients were asked each of the following questions: “How often are you worried people may unintentionally discover your HIV status because of your current HIV treatment?”; “How often are you worried about forgetting to take your HIV medication?”; and “How often is taking your HIV medication an uncomfortable reminder of your HIV status?” Patients who responded “always” or “often” to any of these questions were counted one time for the endpoints above.1
-
SOLAR Study Design
SOLAR is the first head-to-head switch study comparing every-2-month CABENUVA with continuing daily oral BIKTARVY1,2
A large phase 3b, open-label, noninferiority study of virologically suppressed* adults (≥18 years) with HIV-1
- Efficacy analyses, baseline questionnaire, and preference calculation were based on the mITT-E (N=670) population. After consultation with a blinded external expert, 11 participants at a single study site were excluded from the ITT-E population due to critical findings related to significant and persistent noncompliance to protocol requirements
- Safety analyses were based on ITT-E (N=681) population
- Suppression defined as plasma HIV-1 RNA <50 copies/mL. A single prior INSTI-based regimen was allowed for reasons other than treatment failure.1
- 39% (n=173) started with oral lead-in (OLI) and 61% (n=274) of patients in the CABENUVA arm started with injections (SWI) without OLI. OLI regimen consisted of 30-mg cabotegravir and 25-mg rilpivirine once daily given for 1 month; on last day of the OLI period, patients received 2 sets of initiation CABENUVA injections 1 month apart followed by every-2-month injections thereafter.1
- Month 12 (OLI and BIKTARVY) and Month 11 (SWI).1
Meet Miranda
Unfortunately, sometimes having a bottle in your medicine cabinet, you know, it just gives you away.
CABENUVA access and acquisition
Get comprehensive support from benefit verification to reimbursement to acquisition to co-pay collection.
BMI=body mass index; HBV=hepatitis B virus; INSTI=integrase strand transfer inhibitor; ITT-E=intent-to-treat exposed; mITT-E=modified intent-to-treat exposed.
References:
- Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4
- Data on file. ViiV Healthcare group of companies. Durham, NC.
PMUS-CBRWCNT240040
